Lamivudin Sandoz

Lamivudine, the active ingredient in Lamivudin Sandoz, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of Human Immunodeficiency Virus (HIV) infection and chronic hepatitis B infection in adults and adolescents, helping to suppress viral replication and improve clinical outcomes.

GNH USA supplies Lamivudin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudin Sandoz is a nucleoside reverse transcriptase inhibitor used in viral disease management. - HIV infection: reduces viral load and helps restore immune function when used in combination antiretroviral therapy. - Chronic hepatitis B infection: suppresses HBV DNA replication and improves liver enzyme profiles. - HIV‑1 infection in treatment‑experienced patients: provides an alternative NRTI backbone for regimen optimisation.

Lamivudin Sandoz may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Diarrhea: loose stools. - Insomnia: difficulty sleeping. - Elevated liver enzymes: mild hepatic enzyme changes.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring immediate medical attention. - Hepatotoxicity: significant liver injury, potentially leading to jaundice. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Peripheral neuropathy: nerve pain or tingling sensations. - Anemia: reduction in red blood cell count.

Use of Lamivudin Sandoz requires careful clinical monitoring to minimise risks. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: monitor liver enzymes and bilirubin levels during therapy. - Hypersensitivity: discontinue if signs of allergic reaction such as rash or swelling appear. - Pregnancy: evaluate risk‑benefit ratio; use only if clearly needed. - Concomitant medications: review for potential interactions that may affect drug levels. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Lamivudin Sandoz can interact with several agents, altering efficacy or safety.

Major Interactions (Avoid): - Didanosine: combined use increases risk of pancreatitis. - Stavudine: may heighten peripheral neuropathy. - Tenofovir: concurrent use can exacerbate renal toxicity.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, potentially lowering lamivudine concentrations. - Antacids containing aluminum or magnesium: may reduce absorption if taken simultaneously. - Alcohol: can worsen hepatic side effects; monitor liver function.